Plain-English translation of NCT04965454 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Doctors are testing whether two new diagnostic tools can predict how well immune checkpoint inhibitor therapy will work for people with advanced liver cancer that cannot be surgically removed. The first tool is a special type of PET scan using a tracer called fluorine-18 fluorocholine, and the second is a blood test that looks for genetic changes in your cancer. The goal is to figure out before you start treatment whether this medication will likely help you.
Right now, doctors cannot reliably predict which patients will benefit from immune checkpoint inhibitor therapy before starting treatment. This trial exists to see whether these two diagnostic tests can identify patients more likely to respond, which could help doctors choose the best treatment approach for each person.
You likely qualify if…
You likely don't qualify if…
Before you start immune checkpoint inhibitor therapy, you will have two diagnostic tests: a special PET scan that uses a fluorine-18 fluorocholine tracer to look at your tumors, and a blood test to analyze genetic changes in your cancer cells. Depending on what the first scan shows, you may also have a second type of PET scan and another blood test 8 weeks into your treatment. After 16 weeks of treatment, your doctor will use CT or MRI imaging to see how well the therapy is working and compare those results to your initial test results.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
United States